-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 30, Hengrui issued an announcement stating that the clinical trial application of SHR-1701 injection developed by its subsidiary Shengdia was approved by the State Food and Drug Administration, specifically the comparison of SHR-1701 injection combined with axitinib tablets A multicenter, randomized, controlled, open phase Ib/III clinical study of sunitinib malate capsules for the first-line treatment of advanced renal cell carcinoma, and SHR-1701 combined with chemotherapy compared with placebo combined with chemotherapy for the treatment of advanced or untreated advanced renal cell carcinoma.